The recent case of unauthentic Avastin1 carried the dilemma of counterfeit pharmaceuticals to the forefront of illegal commerce. Drug counterfeiters are opportunistic criminals inspired by the windfall profits that are realized from selling fake pharmaceuticals with restricted legal penalties. This article describes the organized trends that could trigger a catastrophic situation of counterfeit drugs infiltrating the international pharmaceutical supply chain – an “ideal storm”.
We argue the failed attempts of the policymakers to note the early warning signals as well as the ease of penetrating the pharmaceutical supply chain--both physically and basically--by an array of illicit traders, that range from modest bungalow businesses to full-scale production facilities; the recent U.S. legislation enacted to curtail growth in counterfeit pharmaceuticals; and the proliferation of national, multilateral, and business-led agencies to protect the prescription drug supply chain. Ultimately, we conclude with an analysis of anti-counterfeiting strategies (e.g., consumer education campaigns, authentication technology) developed by various stakeholders.
PUBLICATION DATE: March 15, 2013 PRODUCT #: BH520-PDF-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
Transforming Human Resources at Novartis: The Human Resources Information System (HRIS)
Memo (Victoria Heavy Equipment)
Trionym Systems: Investment Decision-Making Using Prescriptive Analytics
Amazon Goes Global
In the Know: A Call for the Redesign of Our Knowledge Infrastructure
Performance Management System at Attock Refinery Limited
Foxconn Technology Group (B)
On Weldon’s Watch: Recalls at Johnson & Johnson from 2009 to 2010
Asia Property Ltd.
Environmental Remediation – A Problem to Manage Globally or Locally?
